INO — Inovio Pharmaceuticals Share Price
- $260.92m
- $155.31m
- $0.83m
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 2.22 | ||
Price to Tang. Book | 2.22 | ||
Price to Free Cashflow | n/a | ||
Price to Sales | 292.33 | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | -124.37% | ||
Return on Equity | -85.09% | ||
Operating Margin | -18334.73% |
Financial Summary
Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | 4.11 | 7.41 | 1.77 | 10.26 | 0.83 | 0.35 | 19.8 | -51.33% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Inovio Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines pipeline include INO-3107 for HPV-related recurrent respiratory papillomatosis (RRP); INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, or OPSCC; VGX-3100 for the treatment of Anal or Perianal HSIL; INO-5401 for the treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Treatment of Glioblastoma Multiforme (GBM). Its lead candidate is INO-3107 for the treatment of RRP, a rare and debilitating disease of the respiratory tract caused by HPV infection. Its DNA medicines platform consists of DNA plasmids and its CELLECTRA devices, which are used to deliver the DNA plasmids into the cell. Its CELLECTRA device portfolio consists of two models.
Directors
- Simon Benito NEC (76)
- Jong Kim CEO (52)
- Jay Shepard NVC
- Peter Kies CFO (57)
- Jacqueline Shea COO (55)
- Asli Gevgilili CHO
- Laurent Humeau CSO (54)
- Robert Crotty GCN (47)
- Gene Kim OTH
- Mark Twyman OTH
- Roger Dansey DRC (64)
- David Weiner DRC (65)
- Ann Miller IND (63)
- Wendy Yarno IND (66)
- Lota Zoth IND (61)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- June 15th, 2001
- Public Since
- December 8th, 1998
- No. of Shareholders
- 58
- No. of Employees
- 122
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market
- Shares in Issue
- 25,910,701
![Blurred out image of a map](https://www.stockopedia.com/assets/conversion/images/maps_placeholder.jpg)
- Address
- 6769 Mesa Ridge Rd., SAN DIEGO, 92121
- Web
- https://www.inovio.com/
- Phone
- +1 8584103134
- Auditors
- Ernst & Young LLP
Upcoming Events for INO
Q3 2024 Inovio Pharmaceuticals Inc Earnings Release
Similar to INO
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
As of Today at 21:20 UTC, shares in Inovio Pharmaceuticals are trading at $8.09. This share price information is delayed by 15 minutes.
Shares in Inovio Pharmaceuticals last closed at $8.09 and the price had moved by +1696.58% over the past 365 days. In terms of relative price strength the Inovio Pharmaceuticals share price has outperformed the S&P500 Index by +1329.58% over the past year.
The overall consensus recommendation for Inovio Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Inovio Pharmaceuticals does not currently pay a dividend.
Inovio Pharmaceuticals does not currently pay a dividend.
Inovio Pharmaceuticals does not currently pay a dividend.
To buy shares in Inovio Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $8.09, shares in Inovio Pharmaceuticals had a market capitalisation of $209.62m.
Here are the trading details for Inovio Pharmaceuticals:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: INO
Based on an overall assessment of its quality, value and momentum Inovio Pharmaceuticals is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Inovio Pharmaceuticals is $18.92. That is 133.87% above the last closing price of $8.09.
Analysts covering Inovio Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$4.43 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Inovio Pharmaceuticals. Over the past six months, its share price has outperformed the S&P500 Index by +1492.05%.
As of the last closing price of $8.09, shares in Inovio Pharmaceuticals were trading +51.7% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Inovio Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $8.09.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Inovio Pharmaceuticals' management team is headed by:
- Simon Benito - NEC
- Jong Kim - CEO
- Jay Shepard - NVC
- Peter Kies - CFO
- Jacqueline Shea - COO
- Asli Gevgilili - CHO
- Laurent Humeau - CSO
- Robert Crotty - GCN
- Gene Kim - OTH
- Mark Twyman - OTH
- Roger Dansey - DRC
- David Weiner - DRC
- Ann Miller - IND
- Wendy Yarno - IND
- Lota Zoth - IND